The RalGEF/Ral Pathway
Author:
Publisher
Elsevier
Reference86 articles.
1. Inhibition of Ras for cancer treatment: the search continues;Baines;Future Med. Chem.,2011
2. Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators;Wang;J. Med. Chem.,2013
3. Ral GTPases: corrupting the exocyst in cancer cells;Camonis;Trends Cell Biol.,2005
4. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types;Britten;Cancer Chemother. Pharmacol.,2013
5. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?;Vigil;Nat. Rev. Cancer,2010
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Functional and structural insights into RAS effector proteins;Molecular Cell;2024-08
2. RALGAPA1 Deletion in Belgian Shepherd Dogs with Cerebellar Ataxia;Genes;2023-07-25
3. The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications;Drug Resistance Updates;2022-07
4. Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma;Hepatology;2021-12-17
5. Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer;Cell Reports;2021-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3